POLMON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Polmon, and what generic alternatives are available?
Polmon is a drug marketed by Capellon Pharms Llc and is included in one NDA.
The generic ingredient in POLMON is dexchlorpheniramine maleate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexchlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Polmon
A generic version of POLMON was approved as dexchlorpheniramine maleate by PAI HOLDINGS PHARM on March 23rd, 1984.
Summary for POLMON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Formulation / Manufacturing: | see details |
DailyMed Link: | POLMON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for POLMON
US Patents and Regulatory Information for POLMON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Capellon Pharms Llc | POLMON | dexchlorpheniramine maleate | SYRUP;ORAL | 202520-001 | Jul 16, 2018 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |